Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Bioventures 2014 L.P. Mpm Sells 47,950 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Bioventures 2014 L.P. Mpm sold 47,950 shares of the firm’s stock in a transaction that occurred on Wednesday, November 5th. The shares were sold at an average price of $1.22, for a total transaction of $58,499.00. Following the completion of the sale, the insider owned 5,959,172 shares in the company, valued at $7,270,189.84. This represents a 0.80% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Thursday, November 6th, Bioventures 2014 L.P. Mpm sold 54,452 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.21, for a total transaction of $65,886.92.
• On Tuesday, November 4th, Bioventures 2014 L.P. Mpm sold 140,488 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.22, for a total transaction of $171,395.36.
• On Monday, November 3rd, Bioventures 2014 L.P. Mpm sold 94,063 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.29, for a total transaction of $121,341.27.
• On Friday, October 31st, Bioventures 2014 L.P. Mpm sold 114,044 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.28, for a total transaction of $145,976.32.
• On Thursday, October 30th, Bioventures 2014 L.P. Mpm sold 86,936 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.43, for a total transaction of $124,318.48.
• On Wednesday, October 29th, Bioventures 2014 L.P. Mpm sold 134,240 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.55, for a total transaction of $208,072.00.
• On Tuesday, October 28th, Bioventures 2014 L.P. Mpm sold 69,068 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.64, for a total transaction of $113,271.52.
• On Monday, October 27th, Bioventures 2014 L.P. Mpm sold 72,709 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.72, for a total transaction of $125,059.48.

Werewolf Therapeutics Trading Down 1.6%

Shares of NASDAQ:HOWL traded down $0.02 during mid-day trading on Thursday, reaching $1.20. 647,728 shares of the company’s stock were exchanged, compared to its average volume of 891,846. The firm has a market capitalization of $58.25 million, a price-to-earnings ratio of -0.74 and a beta of 0.72. The business’s fifty day moving average price is $1.61 and its 200-day moving average price is $1.32. The company has a debt-to-equity ratio of 0.73, a quick ratio of 5.30 and a current ratio of 3.87. Werewolf Therapeutics, Inc. has a twelve month low of $0.60 and a twelve month high of $2.41.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. On average, research analysts predict that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Institutional Investors Weigh In On Werewolf Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of HOWL. Jane Street Group LLC bought a new stake in Werewolf Therapeutics in the second quarter valued at $409,000. Marshall Wace LLP bought a new stake in Werewolf Therapeutics in the second quarter valued at $113,000. Y Intercept Hong Kong Ltd bought a new stake in Werewolf Therapeutics in the second quarter valued at $92,000. AQR Capital Management LLC bought a new stake in Werewolf Therapeutics in the first quarter valued at $79,000. Finally, Nuveen LLC bought a new stake in Werewolf Therapeutics in the first quarter valued at $71,000. 64.84% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Zacks Research raised shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 16th. Bank of America lowered their target price on shares of Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, August 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Citigroup reissued a “buy” rating on shares of Werewolf Therapeutics in a research note on Monday, August 25th. Finally, JMP Securities lowered their target price on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research note on Thursday, August 21st. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.